This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound ~~Compounds~~ of ~~the~~ formula I



I

in which

Ar is ~~denotes~~ phenyl, naphthyl, biphenyl, or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

X is ~~denotes~~ -O-, -S-, $-(CH_2)_n-$, -C(=O)-, -CH(OH)-, $-(CH_2)_nO-$, $-O(CH_2)_n-$, $-(CH_2)_nS-$, $-S(CH_2)_n-$, $-(CH_2)_nNH-$, $-NH(CH_2)_n-$, $-(CH_2)_nNA-$, $-NA(CH_2)_n-$, -CHHal-, or $-C(Hal)_2-$,

Y is ~~denotes~~ O, S, $CH\text{-}NO_2$, $C(CN)_2$, or $N\text{-}R^4$,

Z is ~~denotes~~ -Ar, -Ar-X-Ar, $-CH_2-Ar$, or $-CH_2-Ar-X-Ar$,

Het is ~~denotes~~ a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,

R^1 is ~~denotes~~ A, Ar', OR^3, SR^3, OAr', SAr', $N(R^3)_2$, NHAr', Hal, NO_2, CN, $(CH_2)_mCOOR^3$, $(CH_2)_mCON(R^3)_2$, COR^3, $S(O)_mA$, $S(O)_mAr'$, NHCOA, NHCOAr', $NHSO_2A$, $NHSO_2Ar'$, $SO_2N(R^3)_2$, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$, $-NA-(CH_2)_p-NA_2$, $-O-(CH_2)_n-Het^1$, or Het^1,

R^3 is ~~denotes~~ H, A, or $-(CH_2)_nAr'$,

R^4 is ~~denotes~~ H, CN, OH, A, $(CH_2)_mAr'$, COR^3, COAr', $S(O)_mA$, or $S(O)_mAr'$,

Ar' is ~~denotes~~ phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by A, Ph, OH, OA, SH, SA, OPh, SPh, NH_2, NHA, NA_2, NHPh, Hal, NO_2, CN, $(CH_2)_mCOOH$, $(CH_2)_mCOOA$, $(CH_2)_mCONH_2$,

$(CH_2)_mCONHA$, CHO, COA, $S(O)_mA$, $S(O)_mPh$, NHCOA, NHCOPh, $NHSO_2A$, $NHSO_2Ph$, or SO_2NH_2,

Ph is ~~denotes~~ phenyl which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, COOR, COOH, NH_2, NO_2, OH, or OA,

Het^1 is ~~denotes~~ a monocyclic saturated heterocycle having 1 to 4 N, O and/or S atoms, which is ~~may be~~ unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN, $(CH_2)_nOH$, $(CH_2)_nHal$, NH_2, =NH, =N-OH, =N-OA, and/or carbonyl oxygen (=O),

A is ~~denotes~~ alkyl having 1 to 10 C atoms, in which, in addition, 1-7 H atoms are each optionally ~~may be~~ replaced by F and/or chlorine,

Hal is ~~denotes~~ F, Cl, Br, or I,

n is ~~denotes~~ 0, 1, 2, or 3,

m is ~~denotes~~ 0, 1, or 2,

p is ~~denotes~~ 1, 2, 3, or 4, or

~~and~~ a pharmaceutically usable derivative, solvate, salt or stereoisomer ~~derivatives, solvates, salts and stereoisomers~~ thereof, including mixtures thereof in all ratios.

2. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, wherein ~~in which~~ X is ~~denotes~~ O or $-(CH_2)_n-$, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

3. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, wherein ~~in which~~ Ar is ~~denotes~~ Het or phenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1, ~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

4. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, wherein ~~in which~~ R^1 is ~~denotes~~ A, OH, OA, NH_2, NHA, NA_2, Hal, $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$, $(CH_2)_mCONA_2$, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$,

-NA-$(CH_2)_p$-NA_2, -O-$(CH_2)_n$-Het^1, or Het^1,

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

5. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~ Het is ~~denotes~~ a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms,

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

6. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~ Y is ~~denotes~~ O,

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

7. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~ Z is ~~denotes~~ -Ar,

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

8. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~ Z is ~~denotes~~ phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by A, OH, OA, NH_2, NHA, NA_2, -O-$(CH_2)_p$-NH_2, -O-$(CH_2)_p$-NHA, -O-$(CH_2)_p$-NA_2, -NH-$(CH_2)_p$-NH_2, -NH-$(CH_2)_p$-NHA, -NH-$(CH_2)_p$-NA_2, -NA-$(CH_2)_p$-NH_2, -NA-$(CH_2)_p$-NHA, -NA-$(CH_2)_p$-NA_2, -O-$(CH_2)_n$-Het^1, ~~or~~ Het^1, or Hal,

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

9. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~

X is ~~denotes~~ O,

Ar is ~~denotes~~ Het or phenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

R^1 is ~~denotes~~ A, OH, OA, NH_2, NHA, NA_2, Hal, -O-$(CH_2)_p$-NH_2, -O-$(CH_2)_p$-NHA, -O-$(CH_2)_p$-NA_2, -NH-$(CH_2)_p$-NH_2, -NH-$(CH_2)_p$-NHA, -NH-$(CH_2)_p$-NA_2, -NA-$(CH_2)_p$-NH_2, -NA-$(CH_2)_p$-NHA, -NA-$(CH_2)_p$-NA_2, $(CH_2)_m$$CONH_2$, $(CH_2)_m$CONHA, $(CH_2)_m$$CONA_2$, -O-$(CH_2)_n$-$Het^1$ or Het^1,

Het is ~~denotes~~ a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms,

Het^1 is ~~denotes~~ a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or monosubstituted by A or $(CH_2)_n$OH,

Y is ~~denotes~~ O,

Z is ~~denotes~~ -Ar,

A is ~~denotes~~ alkyl having 1 to 10 C atoms~~, in which, in addition,~~ wherein 1-7 H atoms are each optionally ~~may be~~ replaced by F and/or chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

m is ~~denotes~~ 0, 1 or 2, and

p is ~~denotes~~ 1, 2, 3 or 4~~,~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

10. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~

X is ~~denotes~~ O,

Ar is ~~denotes~~ Het which is unsubstituted or mono-, di- or trisubstituted by R^1,

R^1 is ~~denotes~~ $(CH_2)_m$$CONH_2$, $(CH_2)_m$CONHA or $(CH_2)_m$$CONA_2$,

Het is ~~denotes~~ furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl,

Het^1 is ~~denotes~~ a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or monosubstituted by A or $(CH_2)_n$OH,

Y is ~~denotes~~ O,

Z is ~~denotes~~ phenyl which is unsubstituted or mono-, di-, tri-, tetra- or

pentasubstituted by A, OH, OA, NH_2, NHA, NA_2, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$, $-NA-(CH_2)_p-NA_2$, $-O-(CH_2)_n-Het^1_a$ ~~or~~ Het^1_a or Hal,

A is ~~denotes~~ alkyl having 1 to 10 C atoms, in which, in addition, wherein 1-7 H atoms are each optionally ~~may be~~ replaced by F and/or chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

m is ~~denotes~~ 0, 1 or 2, and

p is ~~denotes~~ 1, 2, 3 or 4~~,~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

11. (Currently Amended): A compound ~~Compounds~~ according to claim 1, wherein ~~in which~~

Ar is ~~denotes~~ phenyl, naphthyl, biphenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

X is ~~denotes~~ -O- or $-(CH_2)_n-$,

Y is ~~denotes~~ O,

Z is ~~denotes~~ phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1, -phenylene-X-Ar, $-CH_2$-Ar or $-CH_2$-phenylene-X-Ar,

Het is ~~denotes~~ a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms,

Het^1 is ~~denotes~~ a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or monosubstituted by A or $(CH_2)_nOH$,

R^1 is ~~denotes~~ A, OH, OA, NH_2, NHA, NA_2, Hal, $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$, $(CH_2)_mCONA_2$, $S(O)_mA$, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$, $-NA-(CH_2)_p-NA_2$, $-O-(CH_2)_n-Het^1_a$ or Het^1_a,

A is ~~denotes~~ alkyl having 1 to 10 C atoms, in which, in addition, wherein 1-7 H atoms are each optionally ~~may be~~ replaced by F and/or chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

n is ~~denotes~~ 0, 1, 2 or 3,

m is ~~denotes~~ 0, 1 or 2, and

p is ~~denotes~~ 1, 2, 3 or 4,

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

12. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, wherein said compound is selected from: ~~the group~~

N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-chloro-3-trifluoromethylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{4-[5-(3-chloro-4-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide,

N-methyl-4-{4-[5-(2-methoxy-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3-chloro-4-methylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{4-[5-(3-chloro-6-methoxymethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3-chloro-6-methoxymethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-methoxy-5-trifluoromethylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2,5-dimethoxy-4-chlorophenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-bromo-3-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3-trifluoromethoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-tert-butylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3,4-dichlorophenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-chloro-3-methyl-6-methoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2,4-dimethoxy-5-trifluoromethoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-dimethylamino-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-(2-methylaminoethoxy)-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-(2-dimethylaminoethoxy)-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-[(2-dimethylaminoethyl)methylamino]-5-methyl-phenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended): A process ~~Process~~ for the preparation of a compound ~~compounds of the formula I~~ according to claim 1, said process comprising:

~~and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, characterised in that~~

a) for a compound ~~the preparation of compounds of the formula I~~ in which Y denotes O,

reacting a compound of ~~the~~ formula II



II

,

wherein L is ~~in which X and Ar have the meanings indicated in Claim 1, and L denotes~~ Cl, Br, I or a free or reactively functionally modified OH group,

~~is reacted~~ with a compound of ~~the~~ formula III

$Z\text{-}NH_2$ III ,

~~in which Z has the meaning indicated in Claim 1,~~

and/or

converting a base or acid of ~~the~~ formula I ~~is converted~~ into one of its salts.

14. (Currently Amended): A pharmaceutical composition ~~Medicaments~~ comprising at least one compound ~~of the formula I~~ according to Claim 1 ~~and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~ and at least one excipient and/or adjuvant ~~optionally excipients and/or adjuvants~~.

15. (Currently Amended): A method ~~Use of compounds according to Claim 1 and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament~~ for the treatment of a disease ~~diseases~~ in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role, comprising administering to a patient a compound according to claim 1.

16. (Currently Amended): A method ~~Use~~ according to Claim 15, wherein said kinase is ~~which involves~~ Raf kinase.

17. (Currently Amended): A method ~~Use~~ according to Claim 15, wherein said method is ~~of compounds of the formula I for the preparation of a medicament~~ for the treatment of a disease ~~diseases~~ caused, mediated and/or propagated by Raf kinases.

18. (Currently Amended): A method ~~Use~~ according to Claim 17, wherein said ~~where the~~ Raf kinase is ~~selected from the group consisting of~~ A-Raf, B-Raf, or ~~and~~ Raf-1.

19. (Currently Amended): A method ~~Use~~ according to Claim 18, wherein said disease is a ~~where the diseases are selected from the group of~~ hyperproliferative and non-hyperproliferative disease ~~diseases~~.

20. (Currently Amended): A method ~~Use~~ according to Claim 17, where the disease is cancer.

21. (Currently Amended): A method ~~Use~~ according to Claim 17, where the disease is non-cancerous.

22. (Currently Amended): A method ~~Use~~ according to Claim 21 ~~17~~, wherein said ~~where the~~ non-cancerous disease is ~~diseases are selected from the group consisting of~~ psoriasis, arthritis, inflammation, endometriosis, scarring, Heliobacter pylori infection, influenza A, benign prostate hyperplasia, an immunological disease ~~diseases~~, an autoimmune disease, or ~~diseases and~~ an immunodeficiency disease ~~diseases~~.

23. (Currently Amended): A method ~~Use~~ according to claim 17, wherein said disease is ~~where the diseases are selected from the group consisting of~~ melanoma, brain cancer, lung cancer, squamous epithelium cancer, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian cancer, cervical cancer, prostate cancer,

thyroid cancer, lymphoma, chronic leukaemia, or ~~and~~ acute leukaemia.

24. (Currently Amended): A method ~~Use~~ according to claim 15, wherein said disease is ~~where the diseases are selected from the group~~ arthritis, restenosis, [[;]] fibrotic disorder, ~~disorders;~~ disorders mesangial cell proliferation, diabetic nephropathy, malignant nephrosclerosis, a thrombotic microangiopathy syndrome ~~syndromes~~, an organ transplant rejection, a glomerulopathy ~~glomerulopathies~~, a metabolic disorder ~~disorders~~, inflammation, a solid tumour ~~tumours~~, rheumatic arthritis, diabetic neuropathy, or a ~~and~~ neurodegenerative disease ~~diseases~~.

25. (Currently Amended): A method ~~Use~~ according to claim 15, wherein said disease is ~~where the diseases are selected from the group~~ rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, irritable bowel, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, kidney disease, or a and angiogenesis disorder ~~disorders~~.

26. (Currently Amended): A compound of ~~Intermediate compounds of the~~ formula I-1



I-1

wherein ~~in which~~

Ar is ~~denotes~~ phenyl, naphthyl, biphenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

X is ~~denotes~~ -O-, -S-, $-(CH_2)_n-$, -C(=O)-, -CH(OH)-, $-(CH_2)_nO-$, $-O(CH_2)_n-$, $-(CH_2)_nS-$, $-S(CH_2)_n-$, $-(CH_2)_nNH-$, $-NH(CH_2)_n-$, $-(CH_2)_nNA-$, $-NA(CH_2)_n-$, -CHHal-, or $-C(Hal)_2-$,

R is ~~denotes~~ H or A,

Het is ~~denotes~~ a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,

R^1 is ~~denotes~~ A, Ar', OR^3, SR^3, OAr', SAr', $N(R^3)_2$, NHAr', Hal, NO_2, CN, $(CH_2)_mCOOR^3$, $(CH_2)_mCON(R^3)_2$, COR^3, $S(O)_mA$, $S(O)_mAr'$, NHCOA, NHCOAr', $NHSO_2A$, $NHSO_2Ar'$, or $SO_2N(R^3)_2$,

R^3 is ~~denotes~~ H, A or $-(CH_2)_nAr'$-,

Ar' is ~~denotes~~ phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by A, Ph, OH, OA, SH, SA, OPh, SPh, NH_2, NHA, NA_2, NHPh, Hal, NO_2, CN, $(CH_2)_mCOOH$, $(CH_2)_mCOOA$, $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$, CHO, COA, $S(O)_mA$, $S(O)_mPh$, NHCOA, NHCOPh, $NHSO_2A$, $NHSO_2Ph$, or SO_2NH_2,

Ph is ~~denotes~~ phenyl which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, COOR, COOH, NH_2, NO_2, OH or OA,

A is ~~denotes~~ alkyl having 1 to 10 C atoms~~, in which, in addition,~~ wherein 1-7 H atoms are each optionally ~~may be~~ replaced by F and/or chlorine,

Hal is ~~denotes~~ F, Cl, Br or I,

n is ~~denotes~~ 0, 1, 2 or 3, and

m is ~~denotes~~ 0, 1 or 2, or

a solvate, salt, or stereoisomer thereof ~~and solvates, salts and stereoisomers thereof~~,

including mixtures thereof in all ratios.

27. (Currently Amended): A compound ~~Intermediate compounds~~ according to Claim 26, wherein

~~in which~~

X is ~~denotes~~ O,

Ar is ~~denotes~~ Het which is unsubstituted or mono-, di- or trisubstituted by R^1,

R is ~~denotes~~ H or A,

R^1 is ~~denotes~~ $(CH_2)_mCONH_2$, $(CH_2)_mCONHA_1$ or $(CH_2)_mCONA_2$, and

Het is ~~denotes~~ a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms,

~~and solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

28. (New): A compound according to claim 1, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl.

29. (New): A compound according to claim 1, wherein R^1 is methyl, ethyl, phenyl, F-phenyl, Cl- phenyl, bromopheny, tolyl, hydroxyl, methoxy, ethoxy, SCH_3, phenoxy, S-phenyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, aniline, Hal, NO_2, CN, carboxyl, methoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylethyl, aminocarbonyl, N-methylaminocarbonyl, aminocarbonylmethyl, dimethylaminoethyl, formyl, acetyl, propionyl, methylsulfonyl, phenylsulfonyl, acetamino, phenylcarbonylamino, methylsulfonylamino, phenylsulfonylamino, dimethylaminosulfonyl, 2-amino-ethoxy, 2-methylaminoethoxy, 2-dimethylaminoethoxy, 2-aminoethylamino, 2-methylaminoethylamino, 2-dimethylaminoethylamino, (2-aminoethyl)methylamino, (2-methylaminoethyl)methylamino, (2-dimethylaminoethyl)methylamino, 2-(pyrrolidin-1-yl)-ethoxy, 2-(1-piperidin-1-yl)ethoxy, 2-(morpholin-4-yl)ethoxy, 2-(piperazin-1-yl)ethoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 2-(1-methylpiperidin-4-yl)ethoxy, 2-(4-hydroxyethylpiperazin-1-yl)ethoxy, 2-(4-hydroxypiperidin-1-yl)ethoxy, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 1-piperazinyl, 4-methylpiperazin-1-yl, 4-piperidinyl, 1-methylpiperidin-4-yl, 4-hydroxyethylpiperazin-1-yl, 4-hydroxypiperidin-1-yl.

30. (New): A compound according to claim 1, wherein Ar is o-, m- or p-tolyl, biphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-, m- or p-mercaptophenyl, o-, m- or p-phenoxyphenyl, o-, m- or p-anilino, o-, m- or p-methylaminophenyl, o-, m- or p-phenylaminophenyl, o-, m- or p-fluorophenyl, o-, m- or p-chlorophenyl, o-, m- or p-bromophenyl, o-, m- or p-nitrophenyl, o-, m- or p-cyanophenyl, o-, m- or p-carboxyphenyl, o-, m- or p-carboxymethylphenyl, o-, m- or p-methoxycarbonylphenyl, o-, m- or p-methoxy-carbonylmethylphenyl, o-, m- or p-aminocarbonylphenyl, o-, m- or

p-methylaminocarbonylphenyl, o-, m- or p-formylphenyl, o-, m- or p-acetylphenyl, o-, m- or p-methylsulfonylphenyl, o-, m- or p-methylcarbonylaminophenyl, o-, m- or p-methylsulfonylaminophenyl, o-, m- or p-aminosulfonylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 2-amino-3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl, 2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, or 3-fluoro-4-methoxyphenyl.

31. (New): A compound according to claim 1, wherein Ar is

2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, furthermore preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl,

which in each case is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1.

32. (New): A compound according to claim 1, wherein Ar' is o-, m- or p-tolyl, biphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-, m- or p-mercaptophenyl, o-, m- or p-phenoxyphenyl, o-, m- or p-anilino, o-, m- or p-methylaminophenyl, o-, m- or

p-phenylaminophenyl, o-, m- or p-fluorophenyl, o-, m- or p-chlorophenyl, o-, m- or p-bromophenyl, o-, m- or p-nitrophenyl, o-, m- or p-cyanophenyl, o-, m- or p-carboxyphenyl, o-, m- or p-carboxymethylphenyl, o-, m- or p-methoxycarbonylphenyl, o-, m- or p-methoxycarbonylmethylphenyl, o-, m- or p-aminocarbonylphenyl, o-, m- or p-methylaminocarbonylphenyl, o-, m- or p-formylphenyl, o-, m- or p-acetylphenyl, o-, m- or p-methylsulfonylphenyl, o-, m- or p-methylcarbonylaminophenyl, o-, m- or p-methylsulfonylaminophenyl, o-, m- or p-aminosulfonylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2.6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 2-amino-3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl, 2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, or 3-fluoro-4-methoxyphenyl.

33. (New): A compound according to claim 1, wherein Het is

2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl, or 2,1,3-benzoxadiazol-5-yl,

which in each case is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1.

34. (New): A compound according to claim 1, wherein Het^1 is 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 1-piperazinyl, 4-methylpiperazin-1-yl, 4-piperidinyl, 1-methyl-piperidin-4-yl, 4-hydroxyethylpiperazin-1-yl, 4-hydroxypiperidin-1-yl, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 5,5-dimethyl-2-oxopyrrolidin-1-yl or 3-oxomorpholin-4-yl.